<DOC>
	<DOCNO>NCT01005537</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , cellular adoptive immunotherapy use autologous lymphocyte , may stimulate immune system different way stop tumor cell grow . Aldesleukin may stimulate lymphocyte kill tumor cell . Giving cyclophosphamide together autologous lymphocyte aldesleukin may effective treatment metastatic melanoma . PURPOSE : This phase I/II trial study side effect give cyclophosphamide together autologous lymphocyte aldesleukin see well work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Cyclophosphamide , Autologous Lymphocytes , Aldesleukin Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety toxicity cellular adoptive immunotherapy autologous tumor-infiltrating lymphocyte ( TIL ) follow cyclophosphamide condition post-infusion aldesleukin ( IL-2 ) patient metastatic melanoma . - Assess duration vivo persistence adoptively transfer lymphocyte . Secondary - Evaluate antitumor effect adoptively transfer autologous TIL follow cyclophosphamide condition post-infusion IL-2 patient . OUTLINE : Patients receive cyclophosphamide IV day -3 -2 autologous tumor-infiltrating lymphocyte ( TIL ) IV day 0 . Beginning 6 hour TIL infusion , patient receive high-dose aldesleukin ( IL-2 ) IV three time daily day 0-5 ( 14 dos ) OR low-dose IL-2 subcutaneously twice daily day 0-14 ( 28 dos ) . Patients may receive two additional course TILs low-dose IL-2 ( without cyclophosphamide ) , indicate . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Inclusion Criteria Histopathological documentation melanoma concurrent diagnosis metastatic disease . 18 75 year age able tolerate highdose cyclophosphamide Bidimensionally measurable disease palpation clinical exam , radiographic imaging ( Xray , CT scan ) . For patient receive HDIL2 , normal cardiac stress test within 182 day prior enrollment required patient 50 year old abnormal ECG , history cardiac disease , family history cardiac disease , hypercholesterolemia hypertension . For leukapheresis , patient must meet follow criterion ( exception require prior approval Apheresis director Principal Investigator ) : Pulse : &gt; 45 &lt; 120 Weight : &gt; 45 kg Temperature : &lt; 38C ( &lt; 100.4 F ) WBC : &gt; 3,000 HCT : &gt; 30 % Platelets : &gt; 100,000 ADDITIONAL INCLUSION CRITERIA FOR T CELL INFUSION Exclusion Criteria Significant cardiovascular abnormality define one following : congestive heart failure , clinically significant hypotension , symptom coronary artery disease , presence cardiac arrhythmia EKG require drug therapy ejection fraction &lt; 50 % ( echocardiogram MUGA ) Patients active infection oral temperature &gt; 38.2 C within 72 hour study entry systemic infection require chronic maintenance suppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>